Redeye provides its initial take on MedCap’s Q1 2026 report, which came in broadly in line with our ...
Besqab's Q1 looks solid to us. While the absence of housing starts (as expected) drove lower-than-ex...
Genovis delivered a Q1 broadly in line with our projections, 17% organic growth and 28% EBITDA margi...
* Q1 EBITDA NOK 10m vs ABGSCe NOK 4m * Pricer transition temporary drag, offset by Vusion momentum *...
Redeye updates its estimates and valuation after Lifco’s Q1 2026 report.
Redeye comments on SSH's Q1 2026 report, which was broadly in line on revenue but softer than expect...
Redeye provides an update after CLS and ClearPoint reached a long-term agreement on the future ramp-...
Redeye has updated its estimates and valuation following Heliospectra’s Q1 2026 report.
Nelly’s Q1 report fell short of our expectations. Sales fell 2% y/y while EBIT, due to higher admin ...
The key conclusion from Siili’s Q1 miss is that the Finnish market is adopting the AI transition slo...
Q1/26 reflects near-term cost headwinds from recent acquisitions masking improving underlying moment...
Hyresintäkterna minskade marginellt till 15,4 MEUR (-1%) och driftnettot till 14,0 MEUR (-4%), främs...
Redeye is quite surprised by the very strong order bookings in the first quarter, which were 41% hig...
Redeye leaves a comment following OncoZenge’s announcement of conditional acceptance of its Clinical...
* Sales +3% vs. ABGSCe (-14% y-o-y), adj. EBIT +39% vs.
Prisma visar stark tillväxt Q1 2026: fastighetsvärdet steg 37 % till över 10 mdkr.
Redeye comments on Neola Medical’s rights issue. We view the announcement as expected, and as we had...
FM Mattsson (FMM B) has outpaced much of the market with a ~80% return the last year.
Siili's Q1 came in below our estimates with sales declining -14% y/y.
Redeye provides an initial comment on the Q1 2026 report from Sdiptech.